Drugs / Intetumumab
Intetumumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00888043 | Mar 2009 → Dec 2014 | cancer | Herbert Hurwitz, MD | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00246012 | May 2005 → Jun 2008 | melanoma | Centocor, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00537381 | May 2007 → Nov 2009 | prostate neoplasm | Centocor, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intetumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00246012 ↗ |
| Known as | CNTO 095 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743032 ↗ |
| Known as | CNTO 95 | “An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer” NCT00537381 ↗ |
| Action | Inhibit | “CNTO 95 is a fully humanized monoclonal antibody that blocks integrin αvβ3 with high affinity.” NCT00888043 ↗ |
| Modality | Monoclonal antibody | “the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95)” NCT00246012 ↗ |
| Route | Intravenous | “Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion” NCT00246012 ↗ |